Lithotripsy Devices Market Size, Share, Opportunities, COVID-19 Impact, And Trends By Type (Extracorporeal Shock Wave Lithotripsy, Intracorporeal Lithotripsy Devices), By Application (Kidney Stones, Bile Duct Stones, Urethral Stones, Pancreatic Stones), By End Users (Hospitals, Ambulatory Surgical Centers, Others), And Geography - Forecasts From 2021 To 2026

The lithotripsy devices market is evaluated at US$829.473 million for the year 2019 and is projected to grow at a CAGR of 3.37% to reach the market size of US$1,046.276 million by the year 2026.

Lithotripsy is a medical technique for removing stones from the kidneys and other organs such as the gallbladder and liver. Kidney stones normally move through the body through urine; however, big stones may cause bleeding, severe discomfort, and urinary tract infections if the body is unable to pass them through urination. Extracorporeal shock wave lithotripsy is the most frequent type of lithotripsy, which employs sound waves to shatter big kidney stones into smaller fragments. Although extracorporeal lithotripsy cannot heal all kidney stones, it is one of the most popular methods for the treatment of kidney stones because of its relative safety and other cost-cutting considerations.

Rising occurrence of kidney stones to drive the market.

Intracorporeal lithotripsy may cure all types of kidney stones, as well as ureteral stones, with a high success rate and few side effects. The rising occurrence of kidney stones is projected to propel the Lithotripsy Device Market forward over the forecast period. Lithotripsy has become the most used procedure for treating kidney stones throughout the years. This is primarily owing to the benefits of its relative safety, low cost, shorter recovery time, and favorable patient results.

Increasing risk of end-stage renal failure linked with urolithiasis to incline market demand.

The increased risk of end-stage renal failure linked with urolithiasis is boosting demand for lithotripsy equipment. According to the European Association of Urology, urinary stone prevalence estimates range from 1% to 20% in 2019. Renal stone frequency is particularly high, more than 10% in nations with a high quality of living, such as Canada, Sweden, or the United States. Over the previous 20 years, certain localities have seen a rise of more than 37 percent. It's been linked to a higher chance of kidney failure in the latter stages. As a result of the rising global prevalence of urolithiasis, safe, effective, and cheap urolithiasis therapy is required.

Growing adoption of devices to propel the market size.

Furthermore, lithotripsy devices may treat all types of kidney stones and have a high success rate for ureteral stones with no severe side effects. Hence, it is gaining acceptance. The Shockwave intravascular lithotripsy (IVL) system has been authorized by the US Food and Drug Administration in February 2021, for the treatment of highly calcified coronary arterial plaques. The technique utilizes a balloon to send sonic pressure waves through soft artery tissue to “preferentially disrupt” hardened plaque and improve stent insertion. As a result, it has the potential to supplant the market-standard rotational and orbital atherectomy devices for certain lesions.

Dangers associated with the technique might restrain the market growth.

Apart from the numerous benefits of the treatment, there are several dangers connected with lithotripsy. Internal bleeding can occur as a result of this therapy, necessitating a blood transfusion. It can produce negative side effects, including kidney damage from an obstruction in the urine route caused by small stone particles. There are additional problems that limit the market, such as high blood pressure. Furthermore, the negative consequences of lithotripsy shock waves can result in hypertension, diabetes, and, in some circumstances, irreversible loss of functional renal volume, all of which operate as significant hurdles to the market for lithotripsy devices.

Recent Key Developments in the market.

Dornier MedTech (Dornier) has become the first integrated urology firm in the world to receive certification under the European Union's new medical device legislation (MDR), in March 2021. Clinicians will have access to the highest quality equipment as they deal with the region's rising prevalence of kidney stone disease. Dornier received MDR certification for two of its Class IIb products: the Dornier Delta® III, one of the most powerful lithotripters on the market that uses Dornier's Extracorporeal Shock Wave Lithotripsy (ESWL) technology, and the Dornier UIMSTM, a cutting-edge information management software that provides enhanced imaging and efficiency to help clinicians treat kidney stones.

Boston Scientific has agreed to buy Lumenis LTD's surgical business for $1.07 billion, subject to closing adjustments, from Baring Private Equity Asia (BPEA), in March 2021. Lumenis LTD. is a privately held firm that develops and commercializes energy-based medical solutions. Lumenis surgical business comprises premium laser systems, fibers, and accessories used for urology and otolaryngology operations, with net sales expected to reach about $200 million in 2021. The unique MOSES technology, which has proven exceptional clinical results and efficiency in the care of patients with kidney stones, is the cornerstone of its urology offering.

North America holds the largest share in the lithotripsy devices market. The United States, which is a worldwide leader in terms of technological advancement in the healthcare sector and home to numerous promising research endeavors in the area, has the highest share of the global lithotripsy market in North America. Over the forecast period, the high frequency of kidney stones in the United States is expected to continue to drive the lithotripsy market in the Americas. As per the Centers for Disease Control and Prevention, chronic kidney disease affects about 37 million individuals, or one out of every seven adults, or 15% of the adult population. Over 50,000 lithotripsy operations are performed yearly in the United States, which contributes to driving the lithotripsy equipment market.

Due to the widespread availability of modern medical facilities for treating kidney stones, Europe is expected to have the second-biggest share of the global lithotripsy market throughout the projection period.

Lithotripsy Devices Market Scope:

Segmentation:

• By Type
  • Extracorporeal Shock Wave Lithotripsy Devices
  • Intracorporeal Lithotripsy Devices
• By Application
  • Kidney Stones
  • Bile Duct Stones
  • Pancreatic Stones
  • Ureteral Stones
• By End-User
  • Hospitals
  • Ambulatory Surgical Centers
  • Others
• By Geography
  • North America
    • USA
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • UK
    • Germany
    • France
    • Spain
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Israel
    • Others
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Taiwan
    • Thailand
    • Indonesia
    • Others

Frequently Asked Questions (FAQs)

Q1. What is the size of global lithotripsy devices market?
A1. Lithotripsy Devices Market was valued at US$829.473 million in 2019.

Q2. What will be the lithotripsy devices market size by 2026?
A2. The global lithotripsy devices market is projected to reach a total market size of US$1,046.276 million by 2026.

Q3. What are the growth prospects for the lithotripsy devices market?
A3. The lithotripsy devices market is projected to grow at a CAGR of 3.37% during the forecast period.

Q4. What factors are anticipated to drive the lithotripsy devices market growth?
A4. The rising occurrence of kidney stones is projected to propel the lithotripsy devices market forward over the forecast period.

Q5. Which region holds the maximum market share of the lithotripsy devices market?
A5. North America holds the largest share in the lithotripsy devices market.